Segment Information - Schedule of Reconciles Segment Direct Profit or Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Segment Reporting Information [Line Items]
Total research and development	$ 22,841	$ 8,151
Total general and administrative	15,761	5,944
Operating loss	(38,602)	(14,095)
QTORIN Rapamycin for Microcystic LM [Member]
Segment Reporting Information [Line Items]
Total research and development	4,755	1,929
QTORIN Rapamycin for Microcystic LM - Government Grant Income [Member]
Segment Reporting Information [Line Items]
Total research and development	(987)	(141)
QTORIN Rapamycin For Cutaneous VM [Member]
Segment Reporting Information [Line Items]
Total research and development	2,224	296
QTORIN CMC [Member]
Segment Reporting Information [Line Items]
Total research and development	6,953	1,601
Salaries and Stock-based Compensation [Member]
Segment Reporting Information [Line Items]
Total research and development	6,643	2,810
Total general and administrative	7,827	1,935
Consultants [Member]
Segment Reporting Information [Line Items]
Total research and development	1,910	1,040
Total general and administrative	3,285	2,961
Other [Member]
Segment Reporting Information [Line Items]
Total research and development	1,343	616
Total general and administrative	$ 4,650	$ 1,048